
Please try another search
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Solomon H. Snyder | 86 | - | Founder and Chairman of Scientific Advisory Board |
Barbara S. Slusher | 60 | - | Founder and Member of Scientific Advisory Board |
Gilla Kaplan | 78 | 2020 | Independent Director |
Garry A. Neil | 71 | 2020 | President, CEO & Director |
Mitchell Chan | 44 | 2021 | Independent Director |
Jonathan Goldman | 59 | 2024 | Independent Director |
Aaron Kantoff | 39 | 2024 | Independent Director |
Dennis C. Liotta | 77 | - | Member of Scientific Advisory Board |
Anne B. Young | - | - | Member of Scientific Advisory Board |
Ronald T. Borchardt | - | - | Member of Scientific Advisory Board |
Robert H. Lenox | - | - | Member of Scientific Advisory Board |
Samantha Scollard Truex | 53 | 2024 | Independent Director |
June S. Almenoff | 68 | 2021 | Independent Director |
Michael Thomas Heffernan | 61 | 2025 | Independent Chairman of the Board |
Rita I. Jain | 62 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review